Nucleoside Reverse Transcriptase Inhibitors are associated with hyperlactemia and<unk><unk> 
NRTI also cause pancreatitis, myopathy, peripheral neuropathy, anemia, neutropenia, hepatic toxicity
Specifically didanosine (ddI) and stavudine (d4T)
These medicines are no longer first-line agents in the US and Europe, but are in low-middle income countries
Adverse effects of NRTI is by way of mitochondrial toxicity.
NRTI inhibit human DNA polymerase gamma, a key enzyme for mitochondrial replication.
Impaired electron transport chain, leading to leakage of electrons and increased production of reactive oxygen species.
Variable onset of mitochondrial toxicity, and not at any set point in NRTI use. 
NRTI also cause pancreatitis, myopathy, peripheral neuropathy, anemia, neutropenia, hepatic toxicity
Specifically didanosine (ddI) and stavudine (d4T)
These medicines are no longer first-line agents in the US and Europe, but are in low-middle income countries
NRTI inhibit human DNA polymerase gamma, a key enzyme for mitochondrial replication.
Impaired electron transport chain, leading to leakage of electrons and increased production of reactive oxygen species.
Variable onset of mitochondrial toxicity, and not at any set point in NRTI use. 
Use of stavudine and didanosine containing regimens
CD4 count <200 
Additional studies cite a CD4 count less than 500 as a risk factor.
Female 2.5x male
Plasma Triglycerides >2.2mmol/L
Age, as the risk of hyperlactemia increases 50% with every 10 years of aging
Lipodystrophy and lipoatrophy
Associated with dyslipidemia and insulin resistance
Additional studies cite a CD4 count less than 500 as a risk factor.
Associated with dyslipidemia and insulin resistance
HAART-induced lactic acidosis
Sepsis
Metformin-associated lactic acidosis
Ischemia
Infectious mononucleosis
HIV neurologic complications
Cerebral edema in DKA
Toxoplasmosis